Landmark Bio is a leading biopharmaceutical company based in Watertown, MA, specializing in cell and gene therapy, genome editing, and mRNA products. With a state-of-the-art facility for GMP manufacturing and quality control, Landmark Bio offers a comprehensive range of services, including translational research, process and analytical development, regulatory CMC support, and drug development strategy optimization. Their cross-sector network of top-tier partners, extensive experience in integrating novel technologies, and expertise in essential drug development issues make them a highly sought-after development partner.
Landmark Bio's team is composed of industry experts with years of experience in the biopharmaceutical field. Led by Vice President Olga Mollin, who brings over 20 years of industry experience, and supported by Chief Science Officer Andy Topping, a renowned expert in contract development and manufacture of biologics, as well as Senior Fellow Tim Charlebois and Executive Director Mark Namchuk, Landmark Bio is dedicated to turning cutting-edge research into breakthrough therapies. Join their team or collaborate with them to bring your development project to life.
Generated from the website